Generated October 3, 2026.
Overview
JEPI and XYLD are both monthly-income ETFs that sell call options on U.S. large-cap equities to generate income above what dividends alone provide. JEPI pairs an actively managed equity portfolio with equity-linked notes that systematically sell S&P 500 calls, while XYLD tracks the Cboe S&P 500 BuyWrite Index—a mechanical strategy that holds the S&P 500 and sells one-month call options against it. The key distinction is active versus passive: JEPI's manager makes stock-picking decisions; XYLD follows a rules-based index.
How they differ
XYLD's distribution rate of 8.52% exceeds JEPI's 7.30% by about 1.2 percentage points, reflecting tighter call strikes or more consistent call-sale mechanics. JEPI's expense ratio of 0.35% is meaningfully lower than XYLD's 0.60%, though JEPI's $45.7B in assets under management dwarfs XYLD's $3.40B, suggesting vastly different investor bases. The second key difference is the underlying mechanism: JEPI uses equity-linked notes (a structured-product wrapper) to implement its call selling, while XYLD owns actual S&P 500 stocks and sells calls directly against them. JEPI's beta of 0.43 is slightly higher than XYLD's 0.39, though both dampen upside relative to a 1.0-beta S&P 500 position, reflecting the drag from sold calls. JEPI launched in 05/20/2020; XYLD has been running since 06/21/2013, giving it a longer track record.
Who each is best for
JEPI: Fits investors seeking a diversified, actively managed income-generating equity allocation who are comfortable with modest upside caps and value lower fees over maximum yield. The large asset base and institutional backing appeal to accounts prioritizing stability and reliable monthly distributions.
XYLD: Fits investors who want transparent, rules-based call selling tied directly to S&P 500 holdings and are willing to accept a higher expense ratio in exchange for a simpler index structure and higher current yield. Appeals to those with a shorter time horizon for income or less concern about capping long-term capital appreciation.
Key risks to know
- Call cap truncates upside. Both funds sell calls that limit gains in rallies. XYLD's mechanical monthly roll may cap upside more consistently; JEPI's active management may vary strike selection, but both will underperform a buy-and-hold S&P 500 position in sustained bull markets.
- NAV erosion at elevated yields. XYLD's 8.52% distribution rate—well above long-term U.S. equity dividend yields—suggests meaningful return-of-capital treatment. If underlying holdings appreciate slowly, NAV may decline over time, potentially reducing future distribution capacity.
- Structured-product risk in JEPI. JEPI's use of equity-linked notes introduces counterparty credit risk and embedded derivatives complexity absent in XYLD's direct stock holdings. A sharp equity drawdown combined with stress in the structured-product market could impair liquidity or valuation.
- Index rebalance and assignment timing. XYLD's monthly rebalance and call assignment cycle creates predictable roll friction; JEPI's active management may navigate this differently, but both incur turnover costs not fully captured in the expense ratio.
- Concentration in large-cap U.S. equities. Both funds' income depends on selling calls on S&P 500 constituents, exposing investors to sector concentration and U.S. equity-market risk; holdings may overlap significantly.
Bottom line
If you prioritize lower fees and active stock selection with modest yield, JEPI's 0.35% ratio and 42279985212 larger asset base stand out. If you want maximum current yield and transparent index mechanics, XYLD's 8.52% rate and direct S&P 500 exposure fit that profile—though the higher 0.60% ratio and elevated distribution suggest greater reliance on return of capital. Both cap upside and expose you to call assignment in rallies; past performance doesn't predict future results, and distributions aren't guaranteed to remain stable.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.